Home › NDC Lookup › RxCUI directory › RxCUI 1546894

Abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [Triumeq] — RxCUI 1546894

RxNorm drug concept · Semantic branded drug
RxCUI 1546894 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1546894
Official nameAbacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [Triumeq]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asabacavir 600 MG / dolutegravir 50 MG / 3TC 300 MG Oral Tablet [Triumeq]; Triumeq 600 MG / 50 MG / 300 MG Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)51,277 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Dolutegravir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Dolutegravir blocks a step HIV needs to survive inside your body. The virus uses an enzyme called integrase to insert its genetic code into your cells — once it does that, your cel...
  • What exactly does dolutegravir do — how does it fight HIV?
  • You can take dolutegravir with or without food — there's no strict requirement. That said, food does increase how much of the medicine your body absorbs, so taking it with a meal c...
  • Can I take it with food, or does it have to be on an empty stomach?
📖 Read our full Dolutegravir guide →

🕸️ Concept Web — How Abacavir 600 MG / dolutegravir 50 MG / lamivudin... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [Triumeq] RxCUI 1546894

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Abacavir 190521
    • Dolutegravir 1433868
    • Lamivudine 68244
    • Abacavir / dolutegravir / lamivudine 1546887
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Triumeq 1546889
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Abacavir / dolutegravir / lamivudine Oral Tablet 1546886
    • Abacavir / dolutegravir / lamivudine Oral Product 1546884
    • Abacavir / dolutegravir / lamivudine Pill 1546885
    • Abacavir / dolutegravir / lamivudine Oral Tablet [Triumeq] 1546891
    • Triumeq Oral Product 1546892
    • Triumeq Pill 1546893
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet SCD · 1546888
  • Abacavir 600 MG SCDC · 602392
  • Dolutegravir 50 MG SCDC · 1433869
  • Lamivudine 300 MG SCDC · 350655
  • Abacavir / dolutegravir / lamivudine Oral Tablet SCDF · 1546886
  • Abacavir / dolutegravir / lamivudine Oral Product SCDG · 1546884
  • Abacavir / dolutegravir / lamivudine Pill SCDG · 1546885

Brand-Name Concepts

  • Abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG [Triumeq] SBDC · 1546890
  • Abacavir / dolutegravir / lamivudine Oral Tablet [Triumeq] SBDF · 1546891
  • Triumeq Oral Product SBDG · 1546892
  • Triumeq Pill SBDG · 1546893
  • Triumeq BN · 1546889

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 1546894 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
49702-0231-13 30 TABLET, FILM COATED in 1 BOTTLE (49702-231-13) Triumeq ViiV Healthcare Company 2014-08-22
49702-0258-37 1 KIT in 1 CARTON (49702-258-37) * 90 TABLET, FILM COATED... Triumeq PD ViiV Healthcare Company 2022-03-30
Observed labelers: ViiV Healthcare Company (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.